Cognition Therapeutics, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Cognition Therapeutics, Inc. (CGTX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$14.46 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2023-03-23
- Cognition Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2021-06-30 was -$14.46M.
- Cognition Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2021 was -$14.46M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|
| 2021-12-31 | -$14.46M 10-K · filed 2023-03-23 | |
| 2021-06-30 | -$14.46M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |